News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
Cellectis (CLLS)’ UCART123 Administered To First Patient With BPDCN In Phase I Clinical Trial At MD Anderson Cancer Center 8/18/2017
Kite Pharma (KITE) Highlights Publication From The NCI Demonstrating Responses In Patients With Metastatic Solid Tumors Treated With T Cell Receptor (TCR) Therapy Targeting MAGE A3 8/17/2017
Biogen (BIIB) Gained $1 Billion Overnight After Becoming Goldman Sachs' Favorite Biotech 8/17/2017
PolyPid Ltd. Completes Enrollment In Phase Ib/II Study Of D-PLEX In Post-Cardiac Surgery Sternal Infection 8/16/2017
TRACON Pharma (TCON) Announces Positive Results From NCI Phase I/II Trial Of TRC105 And Nexavar In Hepatocellular Cancer Published In Clinical Cancer Research 8/16/2017
U.S. Department Of Defense To Conduct Studies Of Pluristem Therapeutics (PSTI)’s PLX-R18 In A New ARS Project For Use Before Radiation Exposure 8/16/2017
CoCrystal Announces Positive Data From The Successful Completion Of Phase 1a/1b Trial Of The Non-Nucleoside Polymerase Inhibitor CC-31244 For The Treatment Of Chronic Hepatitis C Infection 8/15/2017
H3 Biomedicine Granted Orphan Drug Designation Of H3B-8800 For Treatment Of Acute Myelogenous Leukemia And Chronic Myelomonocytic Leukemia 8/14/2017
Hemispherx (HEB) Human Safety Study Of Intranasal Ampligen With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated 8/14/2017
CARsgen Therapeutics Launches First-In-Class Anti-Claudin18.2 CAR-T Clinical Trial 8/10/2017
KemPharm (KMPH) Announces Preliminary Results From KP415 Pharmacokinetic Single And Multiple Dose Trial 8/10/2017
Sun BioPharma Files Form 10-Q For Second Quarter 2017 And Provides Clinical Update 8/10/2017
Asterias Biotherapeutics Enrolls First Patient in Final Cohort of SCiStar Clinical Trial 8/9/2017
Theravance Biopharma (TBPH) Reports Encouraging Data From First Cohort Of Patients In Phase Ib Clinical Trial Of TD-1473 In Ulcerative Colitis 8/9/2017
Cellectar Biosciences  (CLRB)’ CLR 131 Achieves Overall Survival Of Greater Than 22 Months In Advanced Multiple Myeloma Patients 8/8/2017
Selvita And The Leukemia & Lymphoma Society Announce Partnership To Advance SEL120 Into Phase I For AML Patients 8/8/2017
How To Try An Experimental Drug When You Don't Qualify For A Clinical Trial 8/8/2017
Verona Pharma (VRP.L) Interim Results For The Six Months Ended June 30, 2017 And Clinical Development Update 8/8/2017
Mitobridge’s Novel Treatment Approach For Duchenne Muscular Dystrophy Advances Into Clinical Development 8/8/2017
Novogen (NVGN) Release: Progress Update On Cantrixil (TRXE-002-1) Development 8/7/2017
Generex Biotechnology Corporation (GNBT) Provides Summary Of Ii-Key Hybrid Vaccine Platform 8/7/2017
4 Clinical Projects Shelved From Pfizer (PFE)’s Pipeline 8/3/2017
Spark Therapeutics (ONCE) Unveils Encouraging Hemophilia A Data 8/3/2017
Intec Pharma Reports Clinical Results From Phase I Trial Of Accordion Pill For Cannabinoid Therapies 8/3/2017
Asterias Biotherapeutics Opens Two Additional Clinical Sites For AST-OPC1 SCiStar Study 8/3/2017
DARA BioSciences Discusses Key Goals With Wall Street Analyzer 8/3/2017
Following Recent Death, InVivo Therapeutics (NVIV) Temporarily Halts Enrollment in INSPIRE Study 8/2/2017
Celsion (CLSN) Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients 8/2/2017
Madison Vaccines Announces First Patient Dosed In An Expanded Combination Trial Of MVI-816 Plus Keytruda® For Metastatic, Treatment-Resistant Prostate Cancer 8/2/2017
Aridis Pharma Enrolls First Patients In Global Pivotal Clinical Trial Of Novel Monoclonal Antibody For Treating Acute Pneumonia 8/2/2017
Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study Of APR-246 For The Treatment Of Platinum-Resistant High-Grade Serous Ovarian Cancer 8/2/2017
Bolder BioTechnology, Inc. Announces Initiation Of Phase I Clinical Trial Of BBT-015 For Treating Neutropenia And Acute Radiation Syndrome 8/2/2017
First Human Subject Enrolled In Lumosa (6535.TWO)' LT3001 Trial 8/1/2017
Massachusetts’ Homology Medicines Snags $83.5M to Advance AMEnDR into Human Trials 8/1/2017
NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies 8/1/2017
Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder 8/1/2017
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases 8/1/2017
Proteostasis (PTI) Announces Progression Of PTI-428 And PTI-801 To Longer Duration Studies In CF Subjects 8/1/2017
ViaCyte Announces First Patients Implanted With PEC-Direct Islet Cell Replacement Therapy In International Clinical Trial 8/1/2017
FDA Calls Roche (RHHBY)'s Leukemia Drug a Breakthrough 7/31/2017
Intercept Pharma (ICPT) Release: CONTROL Trial Shows Statin Therapy Reversed LDL Increases To Below Baseline Levels In NASH Patients Treated With OCA 7/31/2017
Mateon Therapeutics (MATN) Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML 7/31/2017
Zosano (ZSAN) Announces Publication F Positive Phase I Data Of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal 7/31/2017
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases 7/31/2017
TrovaGene (TROV) Announces FDA Approval Of IND For Phase Ib/II Trial Of PCM-075 In Patients With Acute Myeloid Leukemia 7/27/2017
NewLink Genetics (NLNK) Announces First Patient Dosed In Phase I Study Of IDO Pathway Inhibitor NLG802 7/27/2017
Seattle Children's Research Institute's Opens CD22 CAR T-Cell Immunotherapy Trial For Children And Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy 7/27/2017
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/27/2017
Drinking Alcohol After Studying Can Improve Memory, Scientific Reports Reveals 7/27/2017
Eli Lilly (LLY) Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs 7/26/2017
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End 7/26/2017
BioPharm Executive: And So It Continues: Let's Get Rid of Clinical Trials (Part 2) 7/26/2017
CureVac Announces Publication In The Lancet Of First-Ever Human Proof-Of-Concept Study Investigating The Safety And Immunogenicity Of A Prophylactic mRNA Vaccine 7/26/2017
Sequoia Sciences, Inc. Receives FDA Fast Track Designation For Vaccine For Urinary Tract Infections Caused By Multidrug-Resistant Bacteria 7/26/2017
Oncolytics Biotech (ONC.TO) To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress 7/26/2017
First Patient Enrolled In Oncoquest's Phase I/II Study Combining Oregovomab With Hiltonol In Recurrent Ovarian Cancer 7/26/2017
Argos (ARGS) Reports Immunogenicity Results Of AGS-004 In HIV Program 7/26/2017
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline 7/25/2017
TrovaGene (TROV) Announces Peer-Reviewed Publication Of First-In-Human Phase I Trial Results With PCM-075, Its Polo-Like Kinase 1 (PLK1) Inhibitor 7/25/2017
Kezar Life Sciences Announces Successful Completion Of Phase Ia Study And Secures $50 Million In Series B Financing 7/25/2017
AntriaBio Announces First Patient Dosed In Phase I Clinical Study Of AB101 7/25/2017
Q Therapeutics, Inc. Release: FDA Allows Q-Cells For First-In-Human Transverse Myelitis Trial 7/25/2017
Axsome (AXSM) Announces AXS-06 (Moseic Meloxicam And Esomeprazole) Meets Primary Endpoint In Phase I Clinical Trial 7/25/2017
Atossa Genetics (ATOS) Completes Enrollment In Endoxifen Phase I Study And Provides Update On Fulvestrant Microcatheter Phase II Study 7/25/2017
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer 7/24/2017
ORYZON Genomics Presents Final Data On The Phase I Trial With ORY-2001 At The Alzheimer's Association International Conference (AAIC-2017) 7/24/2017
NovoCure Announces A Phase Ib Clinical Trial To Evaluate The Safety Of Marizomib And Temozolomide In Combination With Optune® As Adjuvant Therapy In Patients With Glioblastoma 7/24/2017
Johnson & Johnson (JNJ) Announces Encouraging First-In-Human Clinical Data For Investigational HIV Preventive Vaccine 7/24/2017
BioLight Life Sciences Reports Successful Results In Phase I/IIa Clinical Trial For Glaucoma Insert 7/24/2017
Valneva Receives FDA Fast Track Designation For Its Lyme Disease Vaccine Candidate VLA15 7/24/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
uniQure (QURE) Announces The Successful Development And Scale-Up Of Manufacturing Processes For Its Hemophilia B Gene Therapy Program 7/21/2017
Vertex (VRTX) Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials 7/21/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy 7/21/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space 7/20/2017
Trevena (TRVN) To Host 2017 Analyst Day And Announce Results Of ATHENA Open Label Safety Study Of OLINVO 7/20/2017
Celyad Announces Initiation Of The SHRINK Trial 7/20/2017
Intra-Cellular Therapies (ITCI) Presents At The 2017 International College Of Neuro-Psychopharmacology (CINP) Thematic Meeting On Treatment-Resistant Depression 7/20/2017
Data From BioTime (BTX)’s Phase I/IIa Opregen Trial To Be Presented At The 2017 American Academy of Ophthalmology Annual Meeting 7/19/2017
Bioniz Reports Top-Line Phase I Clinical Study Results For BNZ-1, A Novel Multi-Cytokine Inhibitor 7/19/2017
BriaCell Provides Clinical Update On Its Ongoing Phase I/IIa Clinical Study Of BriaVax In Advanced Breast Cancer 7/19/2017
Athenex Announces Commencement Of Patient Enrollment For Oraxol-Plus-Ramucirumab Phase Ib Clinical Trial In Gastric Cancer 7/19/2017
Biothera Announces Initiation Of Phase Ib/II Clinical Study Evaluating Combination Of Imprime PGG And Merck & Co. (MRK)’s KEYTRUDA In Non-Small Cell Lung Cancer 7/19/2017
Opiant Pharma Announces Phase I Data For OPNT002 In Development For The Treatment Of Alcohol Use Disorder 7/19/2017
Cognition Therapeutics Reports Drug-Drug Interaction Results For CT1812, A Disease-Modifying Alzheimer’s Disease Candidate 7/19/2017
Sunesis (SNSS) Announces First Patient Dosed In Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-Inhibitor SNS-062 In Adults With Chronic Lymphocytic Leukemia And Other B-Cell Malignancies 7/19/2017
Ascentage Pharma Approved To Start China Trial Of Apoptosis Drug 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
Capricor (CAPR) Receives Rare Pediatric Disease Designation From FDA For CAP-1002 For Patients With Duchenne Muscular Dystrophy 7/18/2017
Apexigen Announces First Patient Dosed In Phase Ib/II Clinical Trial Of APX005M In Combination With Opdivo (Nivolumab) In Advanced Solid Tumors 7/17/2017
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's AIS-A 20 Million Cell Cohort 7/17/2017
CStone Pharma Release: China's First Fully Human, Full-Length Anti-PD-L1 Monoclonal Antibody Receives Approval To Initiate Clinical Trials By The China Food And Drug Administration 7/17/2017
New Evidence Of Sutro Biopharma ADC's Potency In Human Tumor Xenografts 7/17/2017
Samumed Successfully Completed Phase I Study For Potential Treatment Of Idiopathic Pulmonary Fibrosis 7/17/2017
No Relief For Investors As The FDA Keeps Partial Hold On Repros Therapeutics (RPRX)'s Proellex Program 7/17/2017
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II 7/14/2017
Initiation Of Clinical Trial Collaboration Evaluating Halozyme (HALO)'s PEGPH20 In Combination With Anti-PDL1 Immunotherapy 7/13/2017
FDA Grants Orphan Drug Designation To Mallinckrodt (MNK) Development Product For Potential Treatment Of Duchenne Muscular Dystrophy 7/13/2017
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's Ais-B 10 Million Cell Cohort 7/12/2017
Immunovaccine Achieves Breakthrough In Support Of Developing Personalized Cancer Immunotherapies 7/12/2017
Cara Therapeutics (CARA) Announces Summary Data From Phase I Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease 7/12/2017
Why Biogen (BIIB) Spinoff Bioverativ (BIVV)'s Anemia Drug Could Be A Blockbuster 7/11/2017
BioMarin (BMRN)'s Investigational Gene Therapy For Hemophilia A At 6e13 Vg/Kg Dose Maintains Average Factor VIII Levels Within Normal Range For Over One Year 7/11/2017
ArQule (ARQL) Announces First Patient Dosed In Phase I Trial Of BTK Inhibitor, ARQ 531, For B-Cell Malignancies 7/11/2017
Valerion Therapeutics, LLC Initiates VAL-1221 Dosing In Patients With Pompe Disease 7/11/2017
ViraCyte Completes Phase I Clinical Trial Of Viralym-C 7/11/2017
uniQure (QURE) Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies 7/11/2017
Asterias Biotherapeutics Receives FDA Clearance To Enroll C-4 Patients In SCiStar Study 7/10/2017
Biotech Holdings Ltd. (BIOHF) Announces First Clinical Use Of Microbiome Optimized Autologous Stem Cells 7/10/2017
Boston Biomedical Announces Orphan Drug Designation By FDA For Investigational WT1 Cancer Peptide Vaccine DSP-7888 In Myelodysplastic Syndrome 7/10/2017
BioLineRx Announces Initiation Of Phase Ib/II Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
Mark Your Calendars: 7 Biotechs Facing Important Catalysts in July 7/7/2017
TrovaGene (TROV) Engages Leading CRO In AML To Conduct Phase Ib/II Trial Of PCM-075 7/6/2017
Biohaven (BHVN)'s BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome 7/6/2017
Corium International, Inc. To Present Clinical Results From Pilot Bioequivalence Study Of Once-Weekly Corplex Donepezil Transdermal System At Alzheimer's Association International Conference 2017 7/6/2017
3 Biotechs With Bulging Pipelines That Could Also Become Attractive Takeover Targets 7/6/2017
Entasis Publishes Data Highlighting The Potent And Differentiated Activity Of ETX2514 Combinations Against Drug Resistant Gram-Negative Bacteria Including Acinetobacter And Pseudomonas 7/5/2017
PRANA Biotechnology (PRAN)'s PBT434 Lowers Alpha-Synuclein And Prevents Neurodegeneration 7/5/2017
iLiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase Ib Clinical Study Data 7/5/2017
Celsion (CLSN) Announces Completion Of OVATION Study And Provides Update On Its Immunotherapy Trial In Advanced Stage III And IV Ovarian Cancer 7/5/2017
ProQR Therapeutics B.V. (PRQR)’s Drug Candidate QRX-411 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA 7/5/2017
Boston Biomedical Presents Data For Investigational Cancer Stemness Inhibitor Napabucasin In Metastatic Colorectal And Pancreatic Cancer At ESMO GI 2017 6/30/2017
eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy Into First Oncology Clinical Studies 6/30/2017
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials 6/29/2017
Proteostasis (PTI) Reports Preliminary Data From Phase I Study Of PTI-428 In Patients With Cystic Fibrosis 6/29/2017
Arena (ARNA) Completes Trial Comparing Once-Daily, Extended Release Formulation Of Ralinepag With Twice-Daily, Immediate Release Formulation In Normal Healthy Volunteers 6/29/2017
Pharmaleads Reports Positive Phase I SAD Data With Its Dual Enkephalinase Inhibitor (DENKI) PL265 For The Treatment Of Neuropathic Pain 6/29/2017
ARMO BioSciences Presents Clinical Data On Immunotherapy AM0010 In Advanced Pancreatic Cancer At ESMO World Congress On Gastrointestinal Cancer 2017 6/29/2017
Pharmaleads Reports Positive Phase I SAD Data With Its Dual Enkephalinase Inhibitor (DENKI) PL265 For The Treatment Of Neuropathic Pain 6/29/2017
Apellis Pharma Release: Positive Data From APL-2 Studies Show Rapid And Durable Improvements In LDH And Hemoglobin Levels 6/29/2017
Cytovation Announces Private Fundraising Round Of NOK 20m To Progress Cypep-1 To Phase I Clinical Study 6/29/2017
BeiGene (BGNE) Presents Preliminary Phase I Data On BGB-A317 In Patients With Hepatocellular Carcinoma At The ESMO 19th World Congress On Gastrointestinal Cancer 6/29/2017
Can Merck & Co. (MRK) And Novartis AG (NVS)'s Surprise Heart Drug Success Translate To Blockbuster Sales? 6/29/2017
Micron Biomedical Release: Phase I Clinical Trial Shows Safety And Immunogenicity Of Microneedle Patch For Flu Vaccination For The First Time 6/28/2017
Skin Patch May Be The Future Of Flu Vaccines, Lancet Reveals 6/28/2017
First In Human Administration Of UCART123 In Cellectis (CLLS)’ AML Phase I Clinical Trial At Weill Cornell Medicine, Newyork-Presbyterian Hospital 6/28/2017
Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation In Europe 6/28/2017
KemPharm (KMPH) Strengthens ADHD Prodrug Pipeline With Development Of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate 6/28/2017
ZIOPHARM Oncology (ZIOP) Announces Initiation Of Stereotactic Treatment Cohort In Phase I Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma 6/28/2017
Arrien Pharmaceuticals LLC Announces A Worldwide License Agreement For ARN-6039, A Clinical Stage Oral ROR-Gammat Inverse Agonist For The Treatment Of Psoriasis And Potentially Other Autoimmune Disorders 6/28/2017
Rhythm And Camurus Announce Positive Initial Data For Extended-Release Delivery Of Setmelanotide For The Treatment Of Rare Genetic Disorders Of Obesity 6/27/2017
Atossa Genetics (ATOS) Receives Positive Safety Committee Assessment Of First Cohort Receiving Oral Formulation Of Endoxifen In Phase I Dose Escalation Study 6/27/2017
TrovaGene (TROV) Announces Submission Of Investigational New Drug Application To Initiate Phase Ib/II Clinical Trial Of PCM-075 For Acute Myeloid Leukemia 6/27/2017
MabVax Therapeutics Commences Patient Dosing In MVT-1075 Radioimmunotherapy Phase I Clinical Trial For The Treatment Of Pancreatic, Colon And Lung Cancers 6/27/2017
Chromocell Announces Initiation Of Multiple Ascending Doses Portion Of Phase I Clinical Trial 6/27/2017
Sound Pharmaceuticals, Inc. Completes Enrollment On Meniere's Disease Clinical Trial 6/27/2017
NeuroVive (NVP) And Yungjin Pharmaceutical Company Ltd. Start Clinical Development In Genetic Mitochondrial Disease 6/27/2017
Will AbbVie (ABBV) Outsmart Biosimilars, And Can Clovis Oncology (CLVS) Win The PARP Race? 6/27/2017
Enanta Pharmaceuticals, Inc. Announces New Data On EDP-938, A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV), At The XIX International Symposium On Respiratory Viral Infections 6/26/2017
Synlogic Receives Fast Track Designation In U.S. For Lead Candidate, SYNB1020 6/26/2017
Semnur Announces Successful Phase I/II Trial In Patients With Radicular Pain For Its Lead Product, SP-102 6/26/2017
ImmunoGen (IMGN) Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia 6/26/2017
Zynerba (ZYNE) Initiates ZYN001 Phase I Clinical Program 6/26/2017
Voyager Therapeutics (VYGR) Announces Clinical Trial Update With VY-AADC01 For Advanced Parkinson’s Disease 6/26/2017
Ablynx (ABLYF) Initiates A Single And Multiple Dose Phase I Study Of Caplacizumab In Healthy Japanese Subjects 6/26/2017
Amgen (AMGN) Goes on the Defensive When Critics Call Its Pipeline a Dud 6/23/2017
BIO2017 CARsgen Therapeutics Presented At The 2017 BIO International Convention 6/23/2017
The Lancet Oncology Publishes Anti-Leukemic Activity And Safety Data For Gilteritinib In Relapsed/Refractory Acute Myeloid Leukemia 6/23/2017
Bellicum (BLCM) Announces Clinical Data On BPX-501 At Presidential Symposium Of The 22nd Congress Of The European Hematology Association 6/23/2017
Bellicum (BLCM) Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association 6/23/2017
uniQure (QURE) Announces Clinical Data Presentations At The Upcoming International Society On Thrombosis And Hemostasis (ISTH) Congress 6/23/2017
Sunesis (SNSS) Announces Presentation Of Updated Results From Washington University-Sponsored Phase I/Cohort Expansion Trial Of Vosaroxin Plus Azacitidine In Patients With MDS At The European Hematology Association Annual Meeting 6/23/2017
Positive Phase Ib Data For NewLink Genetics (NLNK)’ IDO Pathway Inhibitor, Indoximod, In Combination With Chemotherapy For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Presented At The European Hematology Association Congress In Madrid, Spain 6/23/2017
Ionis Pharma (IONS) Release: Enrollment In Phase I/IIa Study Of IONIS-HTT Rx In Patients With Huntington's Disease Completed And Open-Label Extension Study To Open In 2H 2017 6/22/2017
Ampio Pharmaceuticals, Inc. (AMPE) Injects First Patient In Final Pivotal Clinical Trial For Ampion BLA 6/22/2017
Summit Therapeutics Presents Data From Phase I Clinical Programme Of Ezutromid At The EPNS Congress 6/22/2017
OncoArendi Therapeutics SA Announces Selection Of Its Second Clinical Development Candidate: OATD-02 For The Treatment Of Multiple Cancers 6/21/2017
RXi Pharma (RXII) Announces Completion Of Enrollment Of Phase I/II Clinical Trial With RXI-109 For Retinal Scarring 6/21/2017
Northwestern University Release: Cold Virus, Stem Cells Tested To Destroy Deadly Brain Cancer 6/21/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
Regeneus (RGS.AX) To Receive Milestone Payment For Successful Phase I 6/21/2017
BIO2017: After IPO, Full Speed Ahead for San Diego’s Tocagen 6/20/2017
Spyryx Biosciences Expands Development Award With Cystic Fibrosis Foundation; Presents Phase I Data For SPX-101 At The European Cystic Fibrosis Conference 6/20/2017
Intezyne Technologies LLC Granted Orphan Drug Designation For IT-139 In Pancreatic Cancer 6/20/2017
Evogene Ltd. (EVGN) Announces Positive Results In Insect Control Seed Trait Program And Advancement To Phase-I Of First Toxin Against Western Corn Rootworm 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
New Data Reveals This New York Biotech's Pipeline Could be a Game Changer 6/19/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines 6/19/2017
ADC Therapeutics Presents First Clinical Data From Its Novel Antibody-Drug Conjugate ADCT-402 At The International Conference On Malignant Lymphoma 6/19/2017
MacroGenics (MGNX) Presents Updated Data From Phase I Study Of MGD010 At Annual European Congress Of Rheumatology (EULAR 2017) 6/19/2017
Pfizer (PFE) Begins Phase I Clinical Trial To Evaluate Investigational Group B Streptococcus Vaccine 6/19/2017
Synlogic Doses First Subject In Phase I Trial Of Novel Class Of Synthetic Biotic Medicines 6/19/2017
Spectrum Pharma (SPPI) Highlights Results Of A Combination Study Of FOLOTYN (Pralatrexate Injection) Plus Romidepsin Presented At The 14th International Conference On Malignant Lymphoma (14-ICML) Meeting 6/19/2017
Ammonett Pharma Granted Orphan Drug Designation From The U.S. FDA For Ibutamoren Mesylate (MK-0677) For Treatment Of Growth Hormone Deficiency 6/19/2017
Celyad Reports Promising Early Results At First Dose Level Of The Solid Arm Of The THINK Trial 6/19/2017
Juno (JUNO) Presents TRANSCEND NHL 001 Trial Data At International Conference On Malignant Lymphoma 6/19/2017
Porton Biopharma Gains Approval To Advance Next Generation Anthrax Vaccine 6/19/2017
NanoBio Corporation And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
BioMarin (BMRN) Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis 2017 Congress 6/16/2017
BeiGene (BGNE) Presents Initial Phase I Data On BTK Inhibitor BGB-3111 Combined With Obinutuzumab At The 14th International Conference On Malignant Lymphoma And Announces Additional Planned Global Registrational Trials For BGB-3111 6/16/2017
ADC Therapeutics Presents Interim Data From The First Clinical Study Of Its Novel Antibody-Drug Conjugate ADCT-301 At The 14-ICML 6/16/2017
Generon (Shanghai) Corporation Ltd. Announces The Initiation Of A Phase I Clinical Study For A-337, A CD3-Activating Bi-Specific Antibody Targeting Epcam To Treat Solid Tumors 6/15/2017
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017
Inovio Pharma (INO) Fully Enrolls 160 Subjects In Puerto Rico For Second Zika Vaccine Phase I Trial; Continues Leadership To Advance An Effective Preventive Solution 6/15/2017
ProQR Therapeutics B.V. (PRQR) R&D Day Highlights Progress On Pipeline And Introduces Axiomer, A Novel Proprietary RNA Technology 6/15/2017
Innate Pharma (IPH.PA ) Release: Dose-Escalation Data Show Favorable Safety Profile And Promising Clinical Activity For IPH4102 6/15/2017
Innate Pharma (IPH.PA ) : Dose-Escalation Data Show Favorable Safety Profile And Promising Clinical Activity For IPH4102 6/15/2017
MabVax Therapeutics Reports Positive Phase I Results For MVT-2163 ImmunoPET Imaging Agent 6/14/2017